Fedratinib
Brand names: Inrebic · Active ingredient: Fedratinib Hydrochloride
In short: INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
What is Fedratinib used for?
INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
⚠ Boxed warning (FDA's strongest warning)
Serious and fatal encephalopathy, including Wernicke's, has occurred in patients treated with INREBIC. Wernicke's encephalopathy is a neurologic emergency. Assess thiamine levels in all patients prior to starting INREBIC. Do not start INREBIC in patients with thiamine deficiency; replete thiamine prior to treatment initiation. While on treatment all patients should receive prophylaxis with daily oral thiamine and should have thiamine levels assessed as clinically indicated. If encephalopathy is suspected, immediately discontinue INREBIC and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize [see Dosage and Administration (2.6), Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Fedratinib dosage
During treatment with INREBIC, all patients should receive prophylaxis with thiamine 100 mg orally daily .
Conduct baseline testing of thiamine (Vitamin B1) levels prior to initiation of INREBIC .
The recommended dosage of INREBIC is 400 mg taken orally once daily for patients with a baseline platelet count of greater than or equal to 50 × 109/L.
Modify the dose for patients using concomitant strong CYP3A4 inhibitors, and in patients with severe renal impairment (creatinine clearance (CLcr) 15 mL/min to 29 mL/min) .
Patients that are on treatment with ruxolitinib before the initiation of INREBIC must taper and discontinue according to the ruxolitinib prescribing information.
Administration Information:
•INREBIC may be taken with or without food. Administration with a high fat meal may reduce the incidence of nausea and vomiting.
•If a dose of INREBIC is missed, the next scheduled dose should be taken the following day.
•For patients who have difficulty swallowing capsule(s) whole or those with a nasogastric tube:
oOpen the capsule(s).
oIn a glass container, mix the content of the capsule(s) with approximately 180 mL of Ensure® Plus liquid nutritional supplement at room temperature [between 20°C to 25°C (68°F to 77°F)].
oPromptly administer the mixture orally or through a nasogastric tube (French size 14 or 16) within 2 hours of preparation.
oIf using a nasogastric tube, flush it with 60 mL of water after administering the mixture .
oDiscard the prepared dose if not given within 2 hours.
Obtain the following blood tests prior to starting treatment with INREBIC, periodically during treatment, and as clinically indicated :
•Thiamine (Vitamin B1) level
•Complete blood count with platelets
•Creatinine and BUN
•Hepatic panel
•Amylase and lipase
Reduce INREBIC dose when administering with strong CYP3A4 inhibitors to 200 mg once daily.
In cases where coadministration with a strong CYP3A4 inhibitor is discontinued, INREBIC dosage should be increased to 300 mg once daily during the first two weeks after discontinuation of the CYP3A4 inhibitor, and then to 400 mg once daily thereafter as tolerated .
Reduce INREBIC dose to 200 mg once daily in patients with severe renal impairment (creatinine clearance (CLcr) 15 mL/min to 29 mL/min as estimated by Cockcroft-Gault (C-G) equation).
Modify dose for hematologic and nonhematologic adverse reactions per Table 1 and Table 2. Discontinue INREBIC in patients unable to tolerate a dose of 200 mg daily. See
Warnings and Precautions
for other mitigating strategies.
Hematologic Adverse Reactions | Dose Reduction
Grade 4 Thrombocytopenia or
Grade 3 Thrombocytopenia with active bleeding | Interrupt dose until resolved to Grade 2 or lower or baseline. Restart dose at 100 mg daily below the last given dose. …
How to take Fedratinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Discuss the following with patients prior to and during treatment with INREBIC.
Encephalopathy, including Wernicke's
Advise patients that serious and fatal encephalopathy, including Wernicke's, has occurred in patients taking INREBIC. Wernicke's encephalopathy is a neurological emergency resulting from acute thiamine (Vitamin B1) deficiency. Advise patients of the need to monitor thiamine levels [see Dosage and Administration (2.1,
2.3
,
2.7)
, and Warnings and Precautions (5.1)]. Instruct patients that they should receive prophylaxis with thiamine 100 mg orally daily while taking INREBIC . Advise patients to seek emergency medical attention for any change in mental status such as confusion, drowsiness or memory impairment, cerebellar abnormalities such as ataxia, and ophthalmic abnormalities such as diplopia and nystagmus. Advise patients to contact their healthcare provider right away if they experience nausea, vomiting, diarrhea, and weight loss unresponsive to treatment resulting in malnutrition and lower thiamine levels, which may lead to Wernicke's encephalopathy . …
Warnings & precautions
Do not take this medicine if: None.
Serious and fatal encephalopathy, including Wernicke's encephalopathy, has occurred in INREBIC-treated patients. Serious cases were reported in 1.3% (8/608) of patients treated with INREBIC in clinical trials and 0.16% (1/608) of cases were fatal.
Wernicke's encephalopathy is a neurologic emergency resulting from thiamine (Vitamin B1) deficiency. Signs and symptoms of Wernicke's encephalopathy may include ataxia, mental status changes, and ophthalmoplegia (e.g., nystagmus, diplopia). Any change in mental status, confusion, or memory impairment should raise concern for potential encephalopathy, including Wernicke's, and prompt a full evaluation including a neurologic examination, assessment of thiamine levels, and imaging. Assess thiamine levels in all patients prior to starting INREBIC. Do not start INREBIC in patients with thiamine deficiency. However, if thiamine levels are low, replete thiamine prior to starting treatment. While on treatment all patients should receive prophylaxis with oral thiamine and should have thiamine levels assessed as clinically indicated. If encephalopathy is suspected, immediately discontinue INREBIC and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize .
Treatment with INREBIC can cause anemia and thrombocytopenia.
Anemia
New or worsening Grade 3 anemia occurred in 34% of INREBIC-treated patients. The median time to onset of the first Grade 3 anemia was approximately 2 months, with 75% of cases occurring within 3 months. Mean hemoglobin levels reached nadir after 12 to 16 weeks with partial recovery and stabilization after 16 weeks. Red blood cell transfusions were received by 51% of INREBIC-treated patients and permanent discontinuation of INREBIC occurred due to anemia in 1% of patients. …
Fedratinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Encephalopathy, including Wernicke's
•Anemia and Thrombocytopenia
•Gastrointestinal Toxicity
•Hepatic Toxicity
•Amylase and Lipase Elevation
•Uveitis
•Major Adverse Cardiac Events
•Thrombosis
•Secondary Malignancies
•Symptom Exacerbation Following Interruption or Discontinuation of Treatment
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data in the WARNINGS AND PRECAUTIONS Section 5.1 Encephalopathy, including Wernicke's, reflect exposure to INREBIC as a single agent in 608 patients who received more than one dose (ranging from 30 mg to 800 mg) in Studies JAKARTA, ARD11936, JAKARTA2, ARD12042, ARD12888, TED12037/TED12015, INT12497, and TES13519, of whom 459 were patients with myelofibrosis, including 97 patients previously treated with ruxolitinib. Among the 608 patients receiving INREBIC, the median drug exposure was 37 weeks and the median number of cycles initiated was 9 cycles. Fifty-nine percent of 608 patients were exposed for 6 months or longer and 39% were exposed for 12 months or longer. …
Drug interactions
Strong CYP3A4 Inhibitors
Coadministration of INREBIC with a strong CYP3A4 inhibitor increases fedratinib exposure . Increased exposure may increase the risk of adverse reactions. Consider alternative therapies that do not strongly inhibit CYP3A4 activity. Alternatively, reduce the dose of INREBIC when administering with a strong CYP3A4 inhibitor .
Strong and Moderate CYP3A4 Inducers
Coadministration of INREBIC with a strong or moderate CYP3A4 inducer can decrease fedratinib exposure . Decreased exposure may reduce the effectiveness of INREBIC. Avoid INREBIC with strong and moderate CYP3A4 inducers.
Dual CYP3A4 and CYP2C19 Inhibitors
Coadministration of INREBIC with a dual CYP3A4 and CYP2C19 inhibitor increases fedratinib exposure . Increased exposure may increase the risk of adverse reactions. Due to potential increase of exposure, patients taking concomitant dual CYP3A4 and CYP2C19 inhibitors require more intensive safety monitoring and, if necessary, dose modifications of INREBIC based on adverse reactions .
CYP3A4, CYP2C19, or CYP2D6 Substrate Drugs
Coadministration of INREBIC with drugs that are CYP3A4 substrates, CYP2C19 substrates, or CYP2D6 substrates increases the concentrations of these drugs, which may increase the risk of adverse reactions of these drugs . …
About this medicine
INREBIC (fedratinib) is a kinase inhibitor with the chemical name N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide dihydrochloride monohydrate. Its empirical formula is C27H36N6O3S∙2HCl∙H2O and a molecular weight of 615.62. Fedratinib exhibits pH-dependent aqueous solubility; it is freely soluble in the acidic condition (>100 mg/mL at pH 1) and practically insoluble in the neutral condition (4 mcg/mL at pH 7.4). The chemical structure is:
INREBIC (fedratinib) is available as 100-mg (equivalent to 117.3 mg of fedratinib dihydrochloride monohydrate) hard gelatin capsules for oral administration. Each capsule contains inactive ingredients of silicified microcrystalline cellulose and sodium stearyl fumarate. The capsule shell contains gelatin, red iron oxide, titanium dioxide and white ink.
How it works: Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f0f55a2a-4e0c-4cba-8571-03e1424486d7. Read the full official label on DailyMed.